| Safety
Possible side effects include stomach irritation,
anxiety, irritability and insomnia. Pregnant and breast-feeding
women are advised to consult their healthcare practitioner
before using CF Support.
This product is not suitable for persons
allergic to bovine products. There is no known
drug interaction.
Suggested Use
As a dietary supplement, take one bottle of NatCell®
CF Support per day. Start with CF Supportl for 8 days,
then CF Support2 for 8 days and finish the cycle with CF
Support1 for 8 days. CF Support1 contains 5.6 ml
of bovine mesenchyme aqueous extract, and 1.4 ml of bovine
adrenal aqueous extract. CF Support2 contains 3.5 ml of
bovine mesenchyme aqueous extract, and 3.5 ml of bovine
adrenal aqueous extract. Serving size: 1 bottle of 7 ml.
References
-
Behan WM, More IA, Behan PO., Mitochondrial
abnormalities in the postviral fatigue syndrome. Acta Neuropathol
(Berl). 1991;83(1):61-5.
-
Bennett RM, Adult growth hormone deficiency
in patients with fibromyalgia. Curr Rheumatol Rep. 2002
Aug;4(4):306-12. Review
-
Berwaerts J, Moorkens G, Abs R., Secretion
of growth hormone in patients with chronic fatigue syndrome.
Growth Horm IGF Res. 1998 Apr;8 Suppl B:127-9.
-
Buchwald D, Herrell R, Ashton S, Belcourt
M, Schmaling K, Sullivan P, Neale M, Goldberg J., A twin study
of chronic fatigue. Psychosom Med, 2001 Nov-Dec;63(6):936-43.
-
Craveri F, De Pascale V., Activity of orally
administered adrenocortical extract. 1. Effect on the survival
test. Boll Chim Farm 1971;110:457-62.
-
Craveri F, De Pascale V., Activity of orally
administered adrenocortical extract. II. Effect on liver glycogenesis
and sodium retention. Boll Chim Farm 1971;110:457-62.
-
Craveri F, De Pascale V., Activity of orally
administered adrenocortical extract. III. Effect in tests
based on muscular work. Boll Chim Farm 1971; 110: 457-62.
-
DeMeirleir K, Bisbal C, Campine I, De Becker,
P, Salehzada, T, Demettre, E and Lebleu, BA., A 37 kDa 25A
binding protein as a potential biochemical marker for chronic
fatigue syndrome. Am J Med, 2000; (108);99-105
-
Demitrack MA Crofford W., Evidence for and
pathophysiologic implications of hypothalamicpituitary-adrenal
axis dysregulation in fibromyalgia and chronic fatigue syndrome.
Ann N Y Acad Sci. 1998 May 1;840:684-97. Review.
-
Dowsett EG, Ramsay AM, McCartney RA, Bell
EJ., Myalgic encephalomyelitis--a persistent enteroviral infection?
Postgrad Med J. 1990 Jul;66(777):526-30.
-
Farrar DJ, Locke SE, Kantrowitz FG, Chronic
Fatigue Syndrome.1: Etiology and Pathogenesis Behavioral Medicine,
1995; 21 (1): 5-16
-
Fulle S, Mecocci P, Fano G, Vecchiet I, Vecchini
A, Racciotti D, Cherubini A, Pizzigallo E, Vecchiet L, Senin
U, Beal MF., Specific oxidative alterations in vastus lateralis
muscle of patients with the diagnosis of chronic fatigue syndrome.
Free Radic Biol Med. 2000 Dec 15;29(12):1252-9.
-
Gaab J, Huster D, Peisen R, Engert V, Schad
T, Schurmeyer TH, Ehlert U, Low-dose dexamethasone suppression
test in chronic fatigue syndrome and health. Psychosom Med.
2002 Mar-Apr;64(2):311-8.
-
Ho-Yen DO, McNamara
I., General practitioners' experience of the chronic fatigue
syndrome. Br J Gen Pract. 1991; Aug;41(349):324-6.
-
Katon W, Walker E., The relationship of chronic fatigue to
psychiatric illness in community, primary care and tertiary
care samples.- Chronic fatigue syndrome- New York: Wiley,
John & Sons Inc. 1993, Ciba Foundation Symposia Series;
no 173: 193-211
-
Keller RH, Lane JL, Klimas N, Reiter WM, Fletcher MA, van
Riel F, Morgan R., Association of HLA class II antigens and
chronic fatigue immune dysfunction syndrome. Clin Infect Dis,
1994; (18): S154-6
-
Klein R, Berg PA, High incidence of antibodies to 5-hydroxy-tryptamine,
gangliosides and phospholipids in patients with chronic fatigue
and fibromyalgia syndrome and their relatives: evidence for
a clinical entity of both disorders. Eur J Med Res, 1995;
(1):21-6
-
Landay AL, Jessop C, Lennette ET, Levyk JA, Chronic Fatigue
Syndrome: clinical condition associated with immune activation.
Lancet, 1991; (338) no 8769:707-12
-
Lane RJ, Barrett MC, Woodrow D, Moss J, Fletcher R, Archard
LC., Muscle fibre characteristics and lactate responses to
exercise in chronic fatigue syndrome. J Neurol Neurosurg Psychiatry.
1998 Mar;64(3):362-7.
-
Levine PH, Whiteside TL, Friberg D, Bryant J, Colclough G,
Herberman RB, Dysfunction of natural killer activity in a
family with chronic fatigue syndrome. Clin Immunol Immunopathol,
1998; (88):96-104
-
Leal-Cerro A, Povedano J, Astorga R, Gonzalez M, Silva H,
Garcia-Pesquera F, Casanueva FF, Dieguez C., The growth hormone
(GH)-releasing hormone-GH-insulin-like growth factor-1 axis
in patients with fibromyalgia syndrome. J Clin Endocrinol
Metab. 1999 Sep;84(9):3378-81.
-
Logan AC, Wong C., Chronic fatigue syndrome: oxidative stress
and dietary modifications. Altern Med Rev. 2001 Oct;6(5):450-9.
Review.
-
MacHale SM, Cavanagh JT, Bennie J, Carroll S, Goodwin GM,
Lawrie SM., Diurnal variation of adrenocortical activity in
chronic fatigue syndrome. Neuropsychobiology. 1998 Nov;38(4):213-7.
-
Manian FA, Simultaneous measurement of antibodies to Epstein-Barr
virus, human herpesvirus 6, herpes simplex virus types 1 and
2, and 14 enteroviruses in chronic fatigue syndrome: is there
evidence of activation of a nonspecific polyclonal immune
response? Clin Infect Dis. 1994 Sep;19(3):448-53.
-
McCully KK, Natelson BH, Iotti S, Sisto S, Leigh JS Jr., Reduced
oxidative muscle metabolism in chronic fatigue syndrome. Muscle
Nerve. 1996 May; 19(5):621-5.
-
Niehans P., Introduction
to cellular therapy. New York, NY. Pageant books, 1960.
-
Ottenweller JE, Sisto SA, McCarty RC, Natelson BH., Hormonal
responses to exercise in chronic fatigue syndrome. Neuropsychobiology.
2001 Jan;43(l):34-41.
-
Richards RS, Roberts TK, McGregor NR, Dunstan RH, Butt HL.,
Blood parameters indicative of oxidative stress are associated
with symptom expression in chronic fatigue syndrome. Redox
Rep. 2000;5(l):35-41.
-
Shepherd C., Hydrocortisone and chronic fatigue syndrome.
Lancet. 1999 May 8;353(9164):161920.
-
Scott LV, Teh J, Reznek R, Martin A, Sohaib A, Dinan TG, Small
adrenal glands in chronic fatigue syndrome: a preliminary
computer tomography study. Psychoneuroendocrinology, 1999;
(24): 75968
-
Scott LV, Medbak S, Dinan TG., Blunted adrenocorticotropin
and cortisol -responses to cortocotropic-releasing hormone
stimulation in chronic fatigue syndrome. Acta Psychiatr Scand
1998;97:450-457.
-
US Department of Health and Human Services. National Center
for Infectuous diseases. Centers for Disease Control and Prevention.
The facts about chronic fatigue syndrome, Atlanta, GA, 1995.
-
Walsh CM, Zainal NZ, Middleton SJ, Paykel ES., A family history
study of chronic fatigue syndrome. Psychiatr Genet, 2001;
Sep;11(3):123-8.
-
Wolfe F, Russell IJ, Vipraio G, Ross K, Anderson J., Serotonin
levels, pain threshold, and fibromyalgia symptoms in the general
population. J Rheumatol, 1997; (24):555-9
|
